Logo image of HUMA

HUMACYTE INC (HUMA) Stock Fundamental Analysis

USA - NASDAQ:HUMA - US44486Q1031 - Common Stock

1.67 USD
+0.05 (+3.09%)
Last: 10/31/2025, 8:00:01 PM
1.69 USD
+0.02 (+1.2%)
Pre-Market: 11/3/2025, 4:12:27 AM
Fundamental Rating

2

Overall HUMA gets a fundamental rating of 2 out of 10. We evaluated HUMA against 534 industry peers in the Biotechnology industry. HUMA has a bad profitability rating. Also its financial health evaluation is rather negative. HUMA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

HUMA had negative earnings in the past year.
In the past year HUMA has reported a negative cash flow from operations.
HUMA had negative earnings in each of the past 5 years.
In the past 5 years HUMA always reported negative operating cash flow.
HUMA Yearly Net Income VS EBIT VS OCF VS FCFHUMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

The Return On Assets of HUMA (-42.31%) is comparable to the rest of the industry.
With a Return On Equity value of -1449.19%, HUMA is not doing good in the industry: 82.40% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -42.31%
ROE -1449.19%
ROIC N/A
ROA(3y)-66.77%
ROA(5y)-54.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HUMA Yearly ROA, ROE, ROICHUMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for HUMA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HUMA Yearly Profit, Operating, Gross MarginsHUMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for HUMA has been increased compared to 1 year ago.
The number of shares outstanding for HUMA has been increased compared to 5 years ago.
HUMA has a better debt/assets ratio than last year.
HUMA Yearly Shares OutstandingHUMA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
HUMA Yearly Total Debt VS Total AssetsHUMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -7.90, we must say that HUMA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of HUMA (-7.90) is worse than 69.29% of its industry peers.
HUMA has a Debt/Equity ratio of 2.97. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 2.97, HUMA is not doing good in the industry: 81.09% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.97
Debt/FCF N/A
Altman-Z -7.9
ROIC/WACCN/A
WACCN/A
HUMA Yearly LT Debt VS Equity VS FCFHUMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

HUMA has a Current Ratio of 2.45. This indicates that HUMA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of HUMA (2.45) is worse than 69.66% of its industry peers.
HUMA has a Quick Ratio of 1.93. This is a normal value and indicates that HUMA is financially healthy and should not expect problems in meeting its short term obligations.
HUMA has a worse Quick ratio (1.93) than 74.53% of its industry peers.
Industry RankSector Rank
Current Ratio 2.45
Quick Ratio 1.93
HUMA Yearly Current Assets VS Current LiabilitesHUMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

HUMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 64.29%, which is quite impressive.
EPS 1Y (TTM)64.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

HUMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.01% yearly.
Based on estimates for the next years, HUMA will show a very strong growth in Revenue. The Revenue will grow by 389.74% on average per year.
EPS Next Y72.48%
EPS Next 2Y31.02%
EPS Next 3Y28.13%
EPS Next 5Y44.01%
Revenue Next Year1596.89%
Revenue Next 2Y1531.24%
Revenue Next 3Y630.61%
Revenue Next 5Y389.74%

3.3 Evolution

HUMA Yearly Revenue VS EstimatesHUMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
HUMA Yearly EPS VS EstimatesHUMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HUMA. In the last year negative earnings were reported.
Also next year HUMA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HUMA Price Earnings VS Forward Price EarningsHUMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HUMA Per share dataHUMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

A more expensive valuation may be justified as HUMA's earnings are expected to grow with 28.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.02%
EPS Next 3Y28.13%

More info and screens

0

5. Dividend

5.1 Amount

HUMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HUMACYTE INC

NASDAQ:HUMA (10/31/2025, 8:00:01 PM)

Premarket: 1.69 +0.02 (+1.2%)

1.67

+0.05 (+3.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/bmo
Earnings (Next)11-07 2025-11-07/bmo
Inst Owners36.8%
Inst Owner Change-0.21%
Ins Owners6.68%
Ins Owner Change0%
Market Cap308.58M
Revenue(TTM)818.00K
Net Income(TTM)-58721000
Analysts81.67
Price Target8.6 (414.97%)
Short Float %17.74%
Short Ratio5.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)99.47%
Min EPS beat(2)-45.54%
Max EPS beat(2)244.48%
EPS beat(4)2
Avg EPS beat(4)51.51%
Min EPS beat(4)-45.54%
Max EPS beat(4)244.48%
EPS beat(8)4
Avg EPS beat(8)11.14%
EPS beat(12)6
Avg EPS beat(12)7.65%
EPS beat(16)9
Avg EPS beat(16)25.7%
Revenue beat(2)0
Avg Revenue beat(2)-51.96%
Min Revenue beat(2)-70.58%
Max Revenue beat(2)-33.34%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)38.17%
PT rev (3m)-14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.39%
EPS NY rev (1m)-11.11%
EPS NY rev (3m)-76.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-61.48%
Revenue NY rev (1m)1.2%
Revenue NY rev (3m)-53.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 377.24
P/FCF N/A
P/OCF N/A
P/B 76.16
P/tB 76.16
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.56
OCFYN/A
SpS0
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.31%
ROE -1449.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.77%
ROA(5y)-54.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 2.97
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.45%
Cap/Sales 218.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.45
Quick Ratio 1.93
Altman-Z -7.9
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)21.4%
Cap/Depr(5y)14.14%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y72.48%
EPS Next 2Y31.02%
EPS Next 3Y28.13%
EPS Next 5Y44.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1596.89%
Revenue Next 2Y1531.24%
Revenue Next 3Y630.61%
Revenue Next 5Y389.74%
EBIT growth 1Y-4.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.92%
EBIT Next 3Y28.21%
EBIT Next 5Y25.39%
FCF growth 1Y-33.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.24%
OCF growth 3YN/A
OCF growth 5YN/A

HUMACYTE INC / HUMA FAQ

What is the fundamental rating for HUMA stock?

ChartMill assigns a fundamental rating of 2 / 10 to HUMA.


What is the valuation status of HUMACYTE INC (HUMA) stock?

ChartMill assigns a valuation rating of 1 / 10 to HUMACYTE INC (HUMA). This can be considered as Overvalued.


Can you provide the profitability details for HUMACYTE INC?

HUMACYTE INC (HUMA) has a profitability rating of 0 / 10.


Can you provide the financial health for HUMA stock?

The financial health rating of HUMACYTE INC (HUMA) is 2 / 10.